

## SUPPLEMENTARY MATERIAL

### **Impact of Glucagon-Like Peptide-1 Agonist Deprescription in Type 2 Diabetes in a Real-World Setting: A Propensity Score Matched Cohort Study**

Amy L. McKenzie, PhD<sup>†</sup>; Shaminie J. Athinarayanan, PhD<sup>†</sup>  
Virta Health, Denver, CO, USA

<sup>†</sup> Amy L. McKenzie and Shaminie J. Athinarayanan contributed equally

Corresponding Author  
[shaminie@virtahealth.com](mailto:shaminie@virtahealth.com)

## SUPPLEMENTARY FIGURE LEGENDS

### **Supplementary Figure 1 Comparison of change in HbA1c and body weight by GLP-1 medication**

Longitudinal change in estimated means from enrollment through 12 months post deprescription or index date:


- A. HbA1c (%) in GLP-1 deprescription cohort by types of GLP-1; all GLP-1, dulaglutide, exenatide, liraglutide and semaglutide
- B. HbA1c (%) in subcohort analysis in those initially prescribed or continued prescribed semaglutide in GLP-1 deprescription and continued GLP-1 therapy cohorts
- C. HbA1c (%) in subcohort analysis in those initially prescribed or continued prescribed dulaglutide in GLP-1 deprescription and continued GLP-1 therapy cohorts
- D. Weight (kg) in GLP-1 deprescription cohort by types of GLP-1; all GLP-1, dulaglutide, exenatide, liraglutide and semaglutide
- E. Weight (kg) in subcohort analysis in those initially prescribed or continued prescribed semaglutide in GLP-1 deprescription and continued GLP-1 therapy cohorts
- F. Weight (kg) in subcohort analysis in those initially prescribed or continued prescribed dulaglutide in GLP-1 deprescription and continued GLP-1 therapy cohorts

### **Supplementary Figure 2 Comparison of nutritional ketosis parameters by cohort**


Longitudinal change in estimated mean (A) percentage days of logging BHB  $\geq 0.3$ mM and (B) BHB (mM) from enrollment to 12 $\pm$ 3 months post deprescription or index date in GLP-1 deprescription, continued GLP-1 therapy, and non-GLP-1 therapy cohorts

Supplementary Figure 1.

a)




d)




● All GLP-1    ■ Dulaglutide    ◆ Exenatide    ■ Liraglutide    ● Semaglutide

b) Semaglutide




● GLP-1 Deprescription Cohort

e) Semaglutide




■ Continued GLP-1 Therapy Cohort

c) Dulaglutide




● GLP-1 Deprescription Cohort

f) Dulaglutide




■ Continued GLP-1 Therapy Cohort

Supplementary Figure 2



● GLP-1 Deprescription Cohort



■ Continued GLP-1 Therapy Cohort